Kornimate/medical-research-clean huggingface dataset:
peripheral treg cell senescence & serum total cholesterol level

Conditions: Hypercholesterolemia

Summary: hypercholesterolemia is a risk factor for the occurrence and development of atherosclerosis. recent animal studies have found that increased serum cholesterol level is associated with peripheral treg cell senescence, but clinical evidence is still lacking. the purpose of this study is to analyze the correlation between human peripheral treg cell senescence and serum total cholesterol level using clinical blood samples, thus laying a foundation for the establishment of novel therapeutic strategies for atherosclerosis based on the regulation of treg cell senescence.

hypercholesterolemia is a risk factor for the occurrence and development of atherosclerosis. recent animal studies have found that increased serum cholesterol level is associated with peripheral treg cell senescence, but clinical evidence is still lacking. the purpose of this study is to analyze the correlation between human peripheral treg cell senescence and serum total cholesterol level using clinical blood samples, thus laying a foundation for the establishment of novel therapeutic strategies for atherosclerosis based on the regulation of treg cell senescence.

Eligibility criteria:
inclusion criteria: 1. age ≥ 30 and ≤ 60 years old with independent behavior ability. 2. the participants need to fully understand the purpose and content of the study, and voluntarily participate in the study and sign the informed consent. exclusion criteria: 1. pregnant or lactating women. 2. acute and severe diseases in the last 3 months, including but not limited to, acute myocardial infarction, acute cerebral infarction, cerebral hemorrhage, circulatory failure, respiratory failure (internal diseases), trauma requiring hospitalization, or undergoes surgery under general anesthesia (surgical diseases). 3. history of severe diseases, including but not limited to, tumors, serious hematological diseases, serious cardiopulmonary diseases (interventional therapy for coronary artery disease, atrial fibrillation, chronic obstructive pulmonary disease, etc.), renal failure, liver failure, old stroke with serious sequelae. 4. have participated in clinical trials in the past 3 months. 5. the investigator considers that not appropriate for inclusion.

Keywords: treg cell senescence hypercholesterolemia total cholesterol
effects of n-acetyl cysteine during primary percutaneous coronary intervention

Conditions: Acute ST Segment Elevation Myocardial Infarction

Summary: the aim of this study is to evaluate the effects of n-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy. in a sub-group of patients coronary flow reserve will be evaluated.


Eligibility criteria:
inclusion criteria: * patients with acute st elevation myocardial infarction undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy (mehran score ≥5) exclusion criteria: * patients \>18 years old with moderate to high risk for contrast induced nephropathy undergoing percutaneous coronary intervention * low risk for contrast induced nephropathy (mehran score \<5) * use of nephrotoxic agents (nsaids, aminoglycosides,recent contrast injection...) * infection * pregnancy, lactation * renal failure requiring dialysis * hepatic failure * allergy to nac * history of asthma * chronic nitrate usage * malignancy * use of corticosteroids * leucocytosis,thrombocytosis,anemia * blood pressure of \>180/100mmhg despite anti-hypertensive therapy
pilot randomized study of paromomycin (aminosidine) vs streptomycin for uncomplicated pulmonary tuberculosis

Conditions: Tuberculosis, Pulmonary

Summary: objectives: i. compare the pharmacokinetics and early bactericidal activity of paromomycin (aminosidine) vs streptomycin for the treatment of uncomplicated pulmonary tuberculosis. ii. compare the tolerability of these two drugs in these patients. iii. establish the relationships between achieved serum concentration, minimal inhibitory concentration, and early bactericidal activity of paromomycin and streptomycin.

protocol outline: this is a randomized study. patients are randomized to one of three treatment arms. patients in arms i and ii receive one of two doses of paromomycin intramuscularly once a day for 3 days. patients in arm iii receive streptomycin intramuscularly once a day for 3 days. all patients then begin a course of standard therapy for tuberculosis.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * microbiologically proven uncomplicated pulmonary tuberculosis positive direct sputum smear for acid-fast bacilli or presumptive diagnosis based on clinical and radiological findings * no known risk factors for multidrug resistant tuberculosis (mdr tb) including: domicile, shelter, or prison exposure to mdr tb within 6 months residence in a specific domicile, shelter, or prison cell block within 6 months of a known outbreak of mdr tb hospitalization, within 6 months, on a medical service or unit in which nosocomial transmission of mdr tb is known to have occurred * no clinical evidence of cns or miliary tuberculosis * hiv seronegative --prior/concurrent therapy-- * biologic therapy: at least 12 weeks since immune modulators (including colony-stimulating factors, interferons, or interleukins) * chemotherapy: no concurrent chemotherapy * endocrine therapy: at least 12 weeks since corticosteroids * other: at least 2 years since treatment or prophylaxis for tuberculosis at least 12 weeks since treatment with any drug with activity against tuberculosis, including: all standard drugs used for tuberculosis clofazimine rifabutin quinolones aminoglycosides at least 12 weeks since pentoxifylline --patient characteristics-- * hematopoietic: absolute neutrophil count at least 1,000/mm3 * renal: creatinine clearance greater than 60 ml/min * pulmonary: no chronic obstructive pulmonary disease * other: not pregnant fertile patients must use effective contraception no history of intolerance or known hypersensitivity to aminoglycosides no known or suspected mycobacterium avium complex infection no other serious, acute infection no diabetes no major organ dysfunction no malignancy requiring chemotherapy

Keywords: bacterial infection immunologic disorders and infectious disorders mycobacterium infection mycobacterium tuberculosis infection rare disease
effectiveness of auricular acupuncture in reducing dental anxiety and pain perception during orthodontic extractions among adolescents

Conditions: Dental Anxiety

Summary: this prospective, randomised, double-blinded cross-over study aims to compare the effectiveness of auricular acupuncture (aa) with placebo sham acupuncture (psa) in reducing dental anxiety, pain perception and physiological responses to stress and anxiety among adolescents during orthodontic extractions. adolescents aged between 10-19 years old who are undergoing orthodontic treatments requiring bilateral premolar extractions will be invited to complete a validated questionnaire to record their dental anxiety level, oral health knowledge, attitudes, practices, demographic and socio-economic factors. during orthodontic extractions, physiological responses including heart rate and oxygen saturation will be measured with a fingertip pulse oximeter throughout the process. the participants will be allocated randomly to one of the two groups in the study. group 1-- auricular acupuncture in their first orthodontic extraction visit and placebo sham acupuncture in their second orthodontic extraction visit. group 2-placebo sham acupuncture in their first orthodontic extraction visit and auricular acupuncture their second orthodontic extraction visit. both acupuncture interventions will be carried out by a hong kong registered chinese medical practitioner. the acupuncture needles are kept in place for 20 minutes to exert its effect before the dental extraction. placebo sham acupuncture will not cause any harm, but the acupuncture points have no reported effect on stress relief. the extraction of premolars will be performed by a hong kong registered dentist. local anesthesia is injected to numb the respective site, then the premolar will be removed with forceps, followed by stopping the bleeding by biting firmly on gauze.


Eligibility criteria:
inclusion criteria: * undergoing orthodontic treatment and require bilateral extraction of premolars. * have parental consent signed by their parent or guardian. * medically fit with either asa i or ii status * have not taken any medications, especially anxiolytics and antidepressants * the premolars to be extracted should be fully erupted and without any signs of ankylosis.

Keywords: dental anxiety dental pain auricular acupunctures
cga-tavi registry to evaluate the predictive value of a cga in predicting tavi outcomes

Conditions: Aortic Valve Stenosis

Summary: registry study to evaluate the predictive value of a comprehensive geriatric assessment with regard to the outcome of a transcatheter aortic valve implantation. it will be evaluated which parts of the comprehensive geriatric assessment (cga) are best suited to predict the therapeutic success of a heart valve implantation in elderly ( \> 80 years) patient. possible participants are all patient of 80 years or above for whom the implantation of a edwards sapien xt aortic valve is planned

transcatheter aortic valve implantation registry with comprehensive geriatric assessment

Eligibility criteria:
inclusion criteria: * scheduled tavi using edwards sapien xt transcatheter heart valve * compliance with the indications of the instructions for use * age of at least 80 years * written informed consent exclusion criteria: * presence of contraindications as to the instructions for use * no possibility for a follow-up
ecog direct brain interface for individuals with upper limb paralysis

Conditions: Tetraplegia; Spinal Cord Injury; Brachial Plexus Injury; Muscular Dystrophy; ALS; Brainstem Stroke

Summary: the purpose of this research study is to demonstrate that individuals with upper limb paralysis due to spinal cord injury, brachial plexus injury, amyotrophic lateral sclerosis and brain stem stroke can successfully achieve direct brain control of assistive devices using an electrocorticography (ecog)-based brain computer interface system.

brain-computer interface (bci) technology aims to establish a direct link for transmitting information between the brain and external devices, offering a natural and rich control signal for prosthetic hands or functional electrical stimulators (fes) to re-animate paralyzed hands. this study focuses on an ecog-based bci system. ecog measures brain activity using electrodes implanted on the surface of the brain. each participant will undergo testing of the ecog direct brain interface for up to 29 days. participants will learn to control computer cursors, virtual reality environments, and assistive devices such as hand orthoses and functional electrical stimulators using neural activity recorded with the ecog sensor.

Eligibility criteria:
inclusion criteria: * limited or no ability to use both hands due to cervical spinal cord injury, brachial plexus injury, brainstem stroke, muscular dystrophy, or amyotrophic lateral sclerosis (als) or other motor neuron diseases * at least 1 year post-injury * live within 1 hour of the university of pittsburgh or willing to stay in pittsburgh while the ecog electrode is implanted (up to 29 days) * additional inclusion criteria must also be reviewed exclusion criteria: * certain implanted devices * presence of other serious disease or disorder that could affect ability to participate in this study * additional exclusion criteria must also be reviewed

Keywords: electrocorticography tetraplegia spinal cord injury brainstem stroke neuroprosthetic brain-computer interface direct brain interface neural activity motor cortex
safety and efficacy of ionis-fb-lrx in up to 120 patients 55 and older with geographic atrophy (ga) secondary to age-related macular degeneration (amd)

Conditions: Geographic Atrophy; Age Related Macular Degeneration

Summary: the purpose of this study is to assess the safety and efficacy of ionis-fb-lrx for up to 120 patients with geographic atrophy secondary to age related macular degeneration

this study will assess changes in complement factor b over a 69-week treatment period in a patient population 55 and older with well-demarcated geographic atrophy secondary to age related macular degeneration

Eligibility criteria:
key inclusion criteria: 1. must have given written informed consent and be able to comply with study requirements 2. females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal. males must be surgically sterile or, if engaged in sexual relations with a female of child bearing potential, the subject must be using an acceptable contraceptive method from the time of signing the informed consent form until at least a period of 13 weeks after the last dose of study drug (isis 696844 or placebo) 3. well-demarcated geographic atrophy due to age related macular degeneration key exclusion criteria: 1. clinically-significant abnormalities in medical history 2. diagnosis of primary or secondary immunodeficiencies of b lymphocyte function, splenectomy, glomerulonephritis or history of recurrent meningococcal disease 3. diabetes mellitus or thyroid disease unless well controlled for a period of at least 3 months 4. clinically-significant abnormalities in screening laboratory values 5. unwillingness to be administered, or history of a serious reaction to protocol required vaccines 6. known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b 7. history or presence of a disease other than amd in study eye

Keywords: geographic atrophy age related macular degeneration ionis-fb-lrx complement factor b
intravenous autologous cd19 car-t cells for r/r b-all

Conditions: Relapsed B Acute Lymphoblastic Leukaemia; Refractory B Acute Lymphoblastic Leukaemia

Summary: this is phase ii / iii, prospective, single arm, open label study to evaluate safety and efficacy of intravenous autologous cd19 car-t cells for relapsed / refractory b-acute lymphoblastic leukaemia


Eligibility criteria:
inclusion criteria: * patients with relapsed/refractory b-all in accordance with world health organization (who) classification by virtue of bm morphology, flow cytometry, cytogenetics and molecular genetics * age between ≥13 to ≤ 65 years * no detectable leukaemia in the csf (cns-1) * cns leukaemia without clinically evident neurological symptoms (cns-2; with \<5 wbc per μl and cytology positive for blasts) * adequate organ function as defined by a creatinine clearance \> 50 ml/min, serum total bilirubin \ 40% * ecog performance status ≤ 2 * life expectancy \> 3 months * post allogeneic hsct must be ≥ day +100 with no evidence of active gvhd and not receiving immunosuppression * female patients of child bearing age must have negative pregnancy test and is on highly effective contraception methods * male patients must use highly effective contraception methods exclusion criteria: * patients with cns-3 leukaemia. * active cancer (other than b-all). * evidence of severe lung, heart (nyha class iii/iv, arrhythmia, av block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder. * presence of active autoimmune disease or atopic allergy. * hiv serology positivity. * active hepatitis b or c infection as evidenced by quantitative viral pcr assay. * uncontrolled sepsis * pregnant / nursing female. * ongoing prednisolone \> 1mg/kg daily or equivalent. * chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-gvhd therapy.
evaluate the safety and efficacy of botulax® in subjects with benign masseteric hypertrophy

Conditions: Benign Masseteric Hypertrophy

Summary: this study is a randomized, double-blind, placebo-controlled, multi-center phase ii optimal dose-finding study to evaluate the safety and efficacy of botulax® in subjects with benign masseteric hypertrophy

a randomized, double-blind, placebo-controlled, multi-center phase ⅱ optimal dose-finding study to evaluate the safety and efficacy of botulax® in subjects with benign masseteric hypertrophy

Eligibility criteria:
inclusion criteria: 1. male and female adults aged 19 or older. 2. sighting, facilitation measurement are judged by the investigator to be the ratio of benign masseteric hypertrophy. 3. subject who understand and willing to perform with the procedures and visiting schedules of clinical trial. 4. subject who voluntarily agree to participate in this clinical trial. exclusion criteria: 1. subject who is clinically significant facial asymmetry in visual measurement by the investigator. 2. fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception. 3. subject who is deemed unable to participate in a clinical trial under the judgement of a investigator.
riluzole in the treatment of bipolar depression

Conditions: Bipolar Depression

Summary: bipolar disorder is a common and often chronic and debilitating mental illness. the depressive phase of bipolar disorder contributes the largest portion of the disorder, and treatment resistant bipolar depression represents a significant public health problem. recent research has suggested that bipolar depression is associated with elevated brain glutamate activity. we hypothesize that riluzole, a drug approved for als which inhibits glutamate activity, will lead to clinical improvement in patients with bipolar depression.

we hypothesize that riluzole will lead to significant reduction in depressive symptoms as measured by the hamilton depression rating scale (ham-d). additionally, improvement in depressive symptoms will be associated with reduced glutamate levels in the anterior cingulate cortex, but not parieto-occipital cortex, both at day two and day 42.

Eligibility criteria:
inclusion criteria: * male or female age 18-65 * meets dsm-iv criteria for bipolar disorder and is currently depressed * current score of \>/= 18 on the hamilton depression scale exclusion criteria: * active psychotic/manic symptoms * lifetime history of schizophrenia or obsessive compulsive disorder * clinically significant medical disease * women who are pregnant or lactating and women who are not using a medically accepted method of contraception.

Keywords: bipolar depression
management of pain respiratory distress at the end of life in newborn palliative care in the delivery room

Conditions: Respiratory Distress; Pain

Summary: the newborn feels pain and the newborn at the end of life, in the delivery room, is potentially exposed to pain and respiratory distress. protocols for the management of end-of-life symptoms in the delivery room are used in current practice with very few validation studies. the protocol used in delivery rooms in alsace uses fentanyl and midazolam intranasally. it has been used for 3 years and seems to provide satisfactory relief to newborn babies. in doing so, it seems to reassure parents about the quality of support and it seems to meet the expectations of professionals in these anxiety-provoking contexts. scientific validation of these practices would allow wider dissemination to other maternity teams.


Eligibility criteria:
inclusion criteria: * premature or term newborn * in the delivery room * in palliative care * no parental opposition to data collection exclusion criteria: * parental refusal or inability to express their consent * minor parents * very probable survival beyond the delivery room * impossibility of giving informed information to the subject (subject in an emergency situation, difficulties in understanding the subject, etc.) * subject under safeguard of justice * subject under guardianship or curatorship

Keywords: newborn
telephone follow-up on outcome after mild traumatic brain injury

Conditions: Brain Concussion

Summary: the purpose of this study is to see whether providing education and counseling after a mild traumatic brain injury will help in preventing symptoms from becoming chronic over the first six months after injury.

this study examines the effect of scheduled telephone calls on the outcome after mild traumatic brain injury (mtbi) or concussion. these calls offer subjects information, focused counseling, and referrals. mtbi is extremely common in the united states, numbering well over a million cases per year. although recovery for most is quite good, 10-20% of persons have persisting symptoms that affect employment, quality of life, and health care expenses. we are examining one means to decrease persisting symptoms by offering early, consistent intervention before symptoms become persistent. the subjects are enrolled in the emergency departments (ed) of the hospital and receive the baseline assessment while still in the ed. subjects are randomly assigned to two groups: group 1 standard care and group 2 standard care, toll-free telephone number, and scheduled telephone calls for follow-up at 1-2 days, 2, 4, 8, and 12 weeks after injury. all subjects are contacted again at 6 months for an outcome assessment that is done over the telephone. on the telephone, subjects are asked about current problems, and are given both information about recovery from mtbi and some counseling on dealing with symptoms or other complaints. they are also given community resources to obtain assistance if needed. telephone call are reviewed by supervisors (physician and psychologist) for adherence to protocol and for training purposes.

Eligibility criteria:
inclusion criteria: * diagnosis consistent with mild traumatic brain injury * glasgow coma scale score 13-15 * loss of consciousness less than or = to 30 minutes * any period of alteration of consciousness or post-traumatic amnesia * age between 16 and 80 * permanent address * ability to communicate in english exclusion criteria: * hospitalization within previous year for traumatic brain injury * prior or current diagnosis of central nervous system or major psychiatric disorder * intoxication sufficient enough to cloud the diagnosis of mild tbi * current alcohol dependence

Keywords: rehabilitation brain injuries directive counseling
upper gastrointestinal lesions in crohn's disease

Conditions: Upper Gastrointestinal Lesions; Crohn's Disease

Summary: a cross-sectional study was performed from 2017 to 2018. consecutive crohn's disease patients diagnosed in the inflammatory bowel disease center of the sixth affiliated hospital of sun yat-sen university were recruited. all patients underwent upper gastrointestinal endoscopy and biopsy by two defined endoscopists and two pathologists, the basic information were collected at the same time, in order to assess the prevalence of upper gastrointestinal involvement, and determine the role of upper gastrointestinal endoscopy in adult crohn's disease patients, irrespective of upper gastrointestinal symptoms.


Eligibility criteria:
inclusion criteria: * age is 18 years old or older * patients with diagnosis of crohn's disease exclusion criteria: * diagnostic data were incomplete * patients with malignant tumor * use of ppis or non-steroidal anti-inflammatory drugs in the preceding 4 weeks